摘要
前列腺癌是男性常见的恶性肿瘤之一,具有较高的发病率和致死率。前列腺特异性抗原(PSA)在前列腺癌筛查中意义重大。随着前列腺癌诊疗研究的深入,各类生物标志物不断被发现,在前列腺癌诊疗全过程发挥着重要作用。使用血液或尿液样本的前列腺健康指数(PHI)、4K评分、PCA3、精选MDx、外泌体智能积分等指标可以有效辅助前列腺的筛查和诊断。血液循环肿瘤细胞(CTC)、循环肿瘤DNA(ctDNA)可用于前列腺癌的风险分层和治疗药物选择、治疗反应监测,以及临床试验替代终点。使用前列腺癌组织样本的基因组前列腺积分、Prolaris积分等可用于前列腺癌的风险分层。文章就基于血液、尿液和其他类型样本的各类前列腺癌生物标志物的临床应用进行综述。
Prostate cancer is one of the most common cancers in males,and it has high incidence rate and mortality rate.Prostate-specific antigen(PSA)plays a role in prostate cancer screening.With the research progress of prostate cancer diagnosis and treatment,various biomarkers have emerged,which play a role in the whole process of prostate cancer diagnosis and treatment.Prostate health index(PHI),4K score,PCA3,selected MDx and exocrine intelligence scores,can effectively assist in the screening and diagnosis of prostate cancer.Blood circulating tumor cells(CTC)and circulating tumor DNA(ctDNA)can be used for the risk stratification of prostate cancer and the selection of therapeutic drugs,therapeutic responses and alternative endpoints of clinical trials.Genomic prostate score and Prolaris score of prostate cancer tissue samples can be used for prostate risk stratification.This review focuses on various biomarkers of prostate cancer in blood,urine and other specimen types.
作者
吴炯
胡嘉华
施美芳
刘涛
戴洁
卢忻怡
邹政
WU Jiong;HU Jiahua;SHI Meifang;LIU Tao;DAI Jie;LU Xinyi;ZOU Zheng(Department of Clinical Laboratory,Shanghai Jiahui International Hospital,Shanghai 200033,China;Youyi Road Community Health Service Center of Baoshan District,Shanghai 201999,China;Shanghai University of Medicine and Health Sciences,Shanghai 201318,China)
出处
《检验医学》
CAS
2023年第2期190-195,共6页
Laboratory Medicine
基金
上海市宝山区科学技术委员会资助项目(21-E-48)。
